Bristol/Otsuka To Submit Abilify Long-Term Efficacy sNDA As Phase IV
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Otsuka/Bristol-Myers Squibb are required to submit an NDA supplement before the end of 2002 on long-term efficacy of its schizophrenia drug Abilify